WallStreetZenWallStreetZen

NASDAQ: TRML
Tourmaline Bio Inc Stock

$13.45-0.21 (-1.54%)
Updated May 24, 2024
TRML Price
$13.45
Fair Value Price
N/A
Market Cap
$344.95M
52 Week Low
$9.18
52 Week High
$48.31
P/E
-3.3x
P/B
0.97x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$32.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.01
Operating Cash Flow
-$26M
Beta
1.39
Next Earnings
Jun 5, 2024
Ex-Dividend
N/A
Next Dividend
N/A

TRML Overview

Talaris Therapeutics Incorporated is a late-clinical stage cell therapy company in the U.S. The company is developing a allogeneic, hematopoietic stem cell transplantation method which, if it succeeds, will transform the standard of care for solid organ transplantation and severe autoimmune diseases, as well as for severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, in a Phase II trial for living donor kidney transplant patients. Talaris was founded in 1988 and is headquartered in Louisville, KY.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRML scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TRML is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TRML is good value based on its book value relative to its share price (0.97x), compared to the US Biotechnology industry average (6.08x)
P/B vs Industry Valuation
TRML is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TRML due diligence checks available for Premium users.

Be the first to know about important TRML news, forecast changes, insider trades & much more!

TRML News

Valuation

TRML price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.3x
Industry
15.58x
Market
32.03x

TRML price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.97x
Industry
6.08x
TRML is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TRML's financial health

Profit margin

Revenue
$0.0
Net Income
-$13.3M
Profit Margin
0%
TRML's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$359.2M
Liabilities
$5.0M
Debt to equity
0.01
TRML's short-term assets ($300.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRML's short-term assets ($300.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRML's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$14.9M
Investing
-$188.9M
Financing
$161.4M
TRML's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TRML vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
TRML$344.95M-1.54%-3.30x0.97x
PGEN$343.29M+1.49%-3.49x3.54x
ANRO$347.34M+9.86%N/A1.80x
AURA$348.29M-4.22%-3.78x1.67x
MGTX$339.86M+2.82%-4.52x2.79x

Tourmaline Bio Stock FAQ

What is Tourmaline Bio's quote symbol?

(NASDAQ: TRML) Tourmaline Bio trades on the NASDAQ under the ticker symbol TRML. Tourmaline Bio stock quotes can also be displayed as NASDAQ: TRML.

If you're new to stock investing, here's how to buy Tourmaline Bio stock.

What is the 52 week high and low for Tourmaline Bio (NASDAQ: TRML)?

(NASDAQ: TRML) Tourmaline Bio's 52-week high was $48.31, and its 52-week low was $9.18. It is currently -72.16% from its 52-week high and 46.51% from its 52-week low.

How much is Tourmaline Bio stock worth today?

(NASDAQ: TRML) Tourmaline Bio currently has 25,646,509 outstanding shares. With Tourmaline Bio stock trading at $13.45 per share, the total value of Tourmaline Bio stock (market capitalization) is $344.95M.

Tourmaline Bio stock was originally listed at a price of $162.50 in May 7, 2021. If you had invested in Tourmaline Bio stock at $162.50, your return over the last 3 years would have been -91.72%, for an annualized return of -56.42% (not including any dividends or dividend reinvestments).

How much is Tourmaline Bio's stock price per share?

(NASDAQ: TRML) Tourmaline Bio stock price per share is $13.45 today (as of May 24, 2024).

What is Tourmaline Bio's Market Cap?

(NASDAQ: TRML) Tourmaline Bio's market cap is $344.95M, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tourmaline Bio's market cap is calculated by multiplying TRML's current stock price of $13.45 by TRML's total outstanding shares of 25,646,509.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.